2.88 USD
+0.04
1.41%
At close Apr 21, 4:00 PM EDT
1 day
1.41%
5 days
0.70%
1 month
-15.29%
3 months
35.85%
6 months
-7.69%
Year to date
23.61%
1 year
14.74%
5 years
-93.60%
10 years
-98.22%
 

About: OncoCyte Corp is a pioneering diagnostics technology company. Its mission is to democratize access to novel molecular diagnostic testing to improve patient outcomes. The company develops diagnostic tests based on liquid biopsies using blood or urine samples for detecting lung, bladder, and breast cancers. In addition, it also develops screening diagnostics as potential replacements for screening imaging procedures that do not meet the needs of patients, health care providers, or payers.

Employees: 49

0
Funds holding %
of 7,419 funds
0
Analysts bullish %
of 3 analysts

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

500% more first-time investments, than exits

New positions opened: 6 | Existing positions closed: 1

100% more funds holding in top 10

Funds holding in top 10: 1 [Q3] → 2 (+1) [Q4]

80% more repeat investments, than reductions

Existing positions increased: 9 | Existing positions reduced: 5

25% more funds holding

Funds holding: 20 [Q3] → 25 (+5) [Q4]

2% less capital invested

Capital invested by funds: $20.4M [Q3] → $20M (-$396K) [Q4]

3.63% less ownership

Funds ownership: 53.6% [Q3] → 49.97% (-3.63%) [Q4]

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$4
39%
upside
Avg. target
$4.42
53%
upside
High target
$5
74%
upside

3 analyst ratings

positive
67%
neutral
33%
negative
0%
Needham
Mike Matson
22% 1-year accuracy
27 / 121 met price target
48%upside
$4.25
Buy
Reiterated
8 Apr 2025
Lake Street
Thomas Flaten
40% 1-year accuracy
4 / 10 met price target
74%upside
$5
Buy
Initiated
28 Mar 2025
Stephens & Co.
Mason Carrico
12% 1-year accuracy
3 / 26 met price target
39%upside
$4
Equal-Weight
Reiterated
26 Mar 2025

Financial journalist opinion

Based on 5 articles about OCX published over the past 30 days

Positive
Zacks Investment Research
2 weeks ago
OncoCyte (OCX) Upgraded to Buy: What Does It Mean for the Stock?
OncoCyte (OCX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
OncoCyte (OCX) Upgraded to Buy: What Does It Mean for the Stock?
Neutral
MCAP MediaWire
2 weeks ago
Oncocyte to Participate in 24th Annual Needham Virtual Healthcare Conference
IRVINE, Calif., April 2, 2025 – PRISM MediaWire – Oncocyte Corp. (Nasdaq: OCX), a leading diagnostics technology company, today announced that Chief Executive Officer Josh Riggs and Chief Financial Officer Andrea James will attend the 24th Annual Needham Virtual Healthcare Conference, taking place from April 7-10, 2025.
Oncocyte to Participate in 24th Annual Needham Virtual Healthcare Conference
Neutral
GlobeNewsWire
2 weeks ago
Oncocyte to Participate in 24th Annual Needham Virtual Healthcare Conference
IRVINE, Calif., April 02, 2025 (GLOBE NEWSWIRE) -- Oncocyte Corp. (Nasdaq: OCX), a leading diagnostics technology company, today announced that Chief Executive Officer Josh Riggs and Chief Financial Officer Andrea James will attend the 24th Annual Needham Virtual Healthcare Conference, taking place from April 7-10, 2025.
Oncocyte to Participate in 24th Annual Needham Virtual Healthcare Conference
Neutral
Seeking Alpha
4 weeks ago
OncoCyte Corporation (OCX) Q4 2024 Earnings Call Transcript
OncoCyte Corporation (NASDAQ:OCX ) Q4 2024 Earnings Conference Call March 24, 2025 5:00 PM ET Company Participants Gabby Woody - Executive Assistant, HR Coordinator Josh Riggs - President and CEO Andrea James - CFO Ekke Schutz - CSO Conference Call Participants Mark Massaro - BTIG Mike Matson - Needham Mason Carrico - Stephens Gabby Woody Joining us today are Oncocyte President and CEO, Josh Riggs; Chief Science Officer, Ekke Schutz; and CFO, Andrea James. We also have our analysts with us as panelists.
OncoCyte Corporation (OCX) Q4 2024 Earnings Call Transcript
Neutral
MCAP MediaWire
4 weeks ago
Oncocyte Reports Successful 2024; Sets Stage for 2025 Catalysts
IRVINE, Calif., March 24, 2025 – PRISM MediaWire – Oncocyte Corp. (Nasdaq: OCX), a diagnostics technology company, today published the following letter to shareholders in conjunction with its fourth quarter results: Fellow Shareholders, Our dynamic team is making swift progress toward delivering a regulated organ transplant rejection monitoring test kit to the market next year.
Oncocyte Reports Successful 2024; Sets Stage for 2025 Catalysts
Neutral
GlobeNewsWire
1 month ago
Oncocyte to Release Fourth Quarter 2024 Results on March 24, 2025
IRVINE, Calif., March 18, 2025 (GLOBE NEWSWIRE) -- Oncocyte Corp. (Nasdaq: OCX), a pioneering diagnostics technology company, today announced that it will report fourth quarter 2024 financial results after the market closes on Monday, March 24, 2025.
Oncocyte to Release Fourth Quarter 2024 Results on March 24, 2025
Neutral
MCAP MediaWire
1 month ago
Oncocyte to Release Fourth Quarter 2024 Results on March 24, 2025
IRVINE, Calif., March 18, 2025 – PRISM MediaWire – Oncocyte Corp. (Nasdaq: OCX), a pioneering diagnostics technology company, today announced that it will report fourth quarter 2024 financial results after the market closes on Monday, March 24, 2025.
Oncocyte to Release Fourth Quarter 2024 Results on March 24, 2025
Neutral
GlobeNewsWire
2 months ago
Oncocyte to Participate in BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference
IRVINE, Calif., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Oncocyte Corp. (Nasdaq: OCX), a pioneering diagnostics technology company, today announced that Chief Executive Officer Josh Riggs and Chief Financial Officer Andrea James will attend BTIG's MedTech, Digital Health, Life Science & Diagnostic Tools Conference in Snowbird, Utah.
Oncocyte to Participate in BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference
Neutral
MCAP MediaWire
2 months ago
Oncocyte to Participate in BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference
IRVINE, Calif., Feb. 11, 2025 – PRISM MediaWire – Oncocyte Corp. (Nasdaq: OCX), a pioneering diagnostics technology company, today announced that Chief Executive Officer Josh Riggs and Chief Financial Officer Andrea James will attend BTIG's MedTech, Digital Health, Life Science & Diagnostic Tools Conference in Snowbird, Utah.
Oncocyte to Participate in BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference
Neutral
MCAP MediaWire
2 months ago
Oncocyte Prices $29.1 Million Equity Offering
IRVINE, Calif., Feb. 10, 2025 – PRISM MediaWire – Oncocyte Corp. (Nasdaq: OCX), a pioneering diagnostics technology company, today announced that it has entered into securities purchase agreements with existing investors for a registered direct offering (“Registered Direct Offering”) and concurrent private placement (“PIPE Offering”).
Oncocyte Prices $29.1 Million Equity Offering
Charts implemented using Lightweight Charts™